In the absence of a credible opposition party to challenge the ANC, perhaps the IMF is best placed to help the party, writes Ayabulela Dlakavu.
The Overseas Investment Office agreed in principle to allow French dairy company Lactalis International to buy the unit from Aspen, said the person, who asked not to be identified because the details aren’t yet public.
The first quarter of 2019 was painful for investors in many companies which make their money from SA consumers, but the bourse in general didn't share their pain – in part thanks to mining shares.
A total of 17 companies have been listed on the exchange, including heavy hitters Naspers, the Standard Bank Group and Sanlam.
Aspen Pharmacare Chief Executive Officer Stephen Saad is having a bad day, after shares in the drugmaker he co-founded more than two decades ago crashed by as much as 50% in Johannesburg.
Aspen expects its new Port Elizabeth sterile anaesthetics manufacturing plant to generate R4bn in exports once it gets into production by 2022/3.
Regulators are scrutinising trades prompted by speculation that Viceroy Research will release a negative report about a JSE-listed company.
The high cost of cancer drugs in South Africa has come under the spotlight with an investigation by the Competition Commission in the country, writes Natalie Schellack.
The Competition Commission announced it will investigate excessive pricing of cancer medication.
The Competition Commission will conduct an investigation into the alleged anti-competitive conduct of Aspen Pharmacare, the DA says.
Aspen has responded to UK reports, which claim that it secretly planned to destroy cancer medicines as a threat to force countries in Europe to allow price hikes.
The pharmaceutical group is expected to receive final approvals to complete the sale of its milk-formula business within weeks, according to people familiar with the matter.
The pharmaceutical group, which has a market cap of R42.4bn, will retain its primary listing on the JSE.
Investors are concerned about the company's massive debt burden.
Aspen Pharmacare's shares plunged to a seven-year low on Friday as an already protracted deal to sell its infant-formula business dragged out even further, choking off cash flows and weighing on financing costs
Aspen Pharmacare is relocating the production of pharmaceuticals for certain illnesses to South Africa from regions including Europe.
Aspen’s share price dropped by about 8% before recovering on the back of rumours that research group Viceroy was investigating the pharmaceutical company.
Aspen has lost its appeal against an Italian Competition Authority ruling, meaning it must now pay a €5.2m fine, the pharmaceutical company has announced.
Aspen says it has not hiked product prices outside the regulatory framework and sees a Competition Commission probe as an opportunity to have allegations against it set aside.
The SA has asked the Competition Commission and the Medicines Control Council to investigate claims of anti-competitive behaviour by pharmaceutical firm Aspen.
This week’s share watch will look in the rubbish bin of 2016 to see if there are any shares that still offer value, according to stocks analyst Kirk Swart.
Somerset WestFinovate PeopleR15 000.00 Per Month Per Month
Cape TownAmazon Development Centre SA (Pty) Ltd
Cape TownTracking Talent
R 11 800 000
R 1 349 000
R 4 750 000
We subscribe to the Press Code.
You choose what you want
News24 on Android
Get the latest from News24 on your Android device.
Terms and Conditions
24.com Terms and Conditions - Updated April 2012
Creating your profile will enable you to submit photos and stories to get published on News24.
This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.